Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

Yue Xi1,2†, Ting Li1,2†, Yun Xi1,2, Xinyi Zeng3, Ying Miao1,2, Rui Guo1,2, Min Zhang1,2* and Biao Li1,2*

Abstract

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer and is susceptible to develop gemcitabine (GEM) resistance. Decreased expression of human equilibrative nucleoside transporter 1 (hENT1) accompanied by compensatory increase of glycolysis is strongly associated with GEM resistance in TNBC. In this study, we investigated the treatment feasibility of combined hENT1 upregulation and miR-143-mediated inhibition of glycolysis for reversing GEM resistance in TNBC.

Methods: Experiments were performed in vitro and in vivo to compare the efficacy of GEM therapies. In this study, we established a stable drug-resistant cell line, GEM-R cells, from parental cells (MDA-MB-231) through exposure to GEM following a stepwise incremental dosing strategy. Then GEM-R cells were transfected by lentiviral plasmids and GEM-R cells overexpressing hENT1 (GEM-R-hENT1) were established. The viability and apoptosis of wild-type (MDA-MB-231), GEM-R, and GEM-R-hENT1 cells treated with GEM or GEM + miR-143 were analyzed by CCK8 assay and flow cytometry. The RNA expression and protein expression were measured by RT-PCR and western blotting respectively. GEM uptake was determined by multiple reaction monitoring (MRM) analysis. Glycolysis was measured by glucose assay and 18F-FDG uptake. The antitumor effect was assessed in vivo in a tumor xenograft model by evaluating toxicity, tumor volume, and maximum standardized uptake value in 18F-FDG PET. Immunohistochemistry and fluorescence photography were taken in tumor samples. Pairwise comparisons were performed using Student’s t-test.

Results: Our results represented that overexpression of hENT1 reversed GEM resistance in GEM-R cells showing lower IC50 and higher rate of apoptosis. MiR-143 suppressed glycolysis in GEM-R cells and enhanced the effect of reversing GEM resistance in GEM-R-hENT1 cells. The therapeutic efficacy was validated using a xenograft mouse model. Combination treatment decreased tumor growth rate and maximum standardized uptake value in 18F-FDG PET more effectively.

Conclusions: Combined therapy of exogenous upregulation of hENT1 expression and miR-143 mimic administration was effective in reversing GEM resistance, providing a promising strategy for treating GEM-resistant TNBC.

Keywords: Triple-negative breast cancer, hENT1, miR-143, Combination therapy, Gemcitabine resistance
characterized by the lack of expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2); for this reason, endocrine or anti-HER2 targeted therapies are not effective [9]. TNBC is more prevalent in younger women and challenging to treat because of a higher rate of relapse and metastasis and a lower survival rate than other types of breast cancer [10, 11]. Since no effective targeted therapies are currently available to improve survival in patients with TNBC because the molecular mechanisms of recurrence are unknown, chemotherapy remains the mainstay of treatment [12]. However, TNBC tends to develop drug resistance, so that affected patients have a higher risk of recurrence and worse prognosis after chemotherapy [13].

Gemcitabine (GEM), an antimetabolite antineoplastic drug [14] that functions as a nucleoside analog and inhibits DNA replication, is useful in the treatment of pancreatic cancer, metastatic breast cancer and so on [15, 16]. GEM is the first-line treatment for metastatic TNBC with or without paclitaxel or other drugs [17–19]. Nevertheless, tumor resistance to GEM increases the risk of relapse and decreases survival and the quality of life [8, 20, 21]. Therefore, reducing tumor resistance to chemotherapy is essential to improve survival and the quality of life of patients with TNBC.

The biochemical mechanisms of drug resistance include [22] reduced drug delivery, uptake, and metabolism, and increased drug efflux and inactivation. Although the molecular mechanisms of drug resistance are incompletely understood, evidence has indicated that transporter proteins play an important role in the uptake and efficacy of chemotherapeutic agents and drug resistance [23, 24]. Human equilibrative nucleoside transporter 1 (hENT1) is a member of nucleoside transmembrane transporter proteins and mediates the cellular uptake of nucleoside drugs such as GEM [25, 26]. Previous studies have demonstrated that hENT1-deficient cells are less sensitive to nucleosides in vitro [27–29]. hENT1 is found downregulated after drug resistance develops in multiple cancers, including pancreatic cancer [30], cholangiocarcinoma [31], and breast cancer [27]. Moreover, the expression level of hENT1 is strongly associated with prognosis and the efficacy of GEM-based therapies in pancreatic [32, 33], lung [34], and breast cancer [27]. These data suggest that upregulating the expression of hENT1 is a potentially effective strategy for reversing GEM resistance and enhancing treatment efficacy in TNBC.

The enhancement of glycolysis is considered to be a compensatory mechanism for tumor cells by downregulating the expression of adenosine transporters to reduce the entry of gemcitabine drugs and adenosine energy substances into the cell [35, 36], and to participate in the resistance of tumor cells to GEM. MicroRNAs (miRNAs) are small endogenous non-coding RNAs that reduce the expression and stability of mRNAs [37, 38]. MIR-143 inhibits glycolysis [39] in glioblastoma [40], gallbladder cancer [41], and breast cancer [42], suggesting its potential as an oncomiR [43, 44], and is markedly downregulated in TNBC. Moreover, miR-143 is associated with tumor invasiveness, metastasis, and chemoresistance [45, 46]. MIR-143 inhibits [44] glycolysis by downregulating hexokinase 2 (HK2), the rate-limiting enzyme in the glycolytic pathway. Therefore, miR-143 can potentially reduce the Warburg effect [47] and reverse GEM resistance in TNBC.

This study proposed a combination therapy involving the exogenous overexpression of hENT1 and the administration of miR-143 mimic to increase GEM uptake and decrease glycolysis in tumor cells, and assessed the efficacy of this therapy to reduce GEM resistance in vitro and in an animal model of TNBC.

Methods
Patient survival analysis
The distal recurrence free survival data of TNBC patients from GSE25066 and GSE69031 was obtained from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) [48] Kaplan–Meier analysis was performed to determine the overall survival of TNBC patients using the online database (http://kmplot.com/analysis/), [49, 50]. The array probe of hENT1(SLC29A1) was 201801_s_at. We selected TNBC patients with ER, PR and HER2 negative status from both array and immunohistochemistry (IHC). The best cut-off was applied.

Patient survival was evaluated with Kaplan–Meier method and log-rank test was used to establish the statistical significance of the distance between curves by Statistical Product and Service Solutions (SPSS) v25.0 and GraphPad Prism v6.0 software.

Cell culture
The human TNBC cell line MDA-MB-231 (wild-type [WT]) was purchased from Cell Bank of the Chinese Academy of Sciences, Shanghai, China. The cell line passed the library mycoplasma test and the results were negative. It has been authenticated by STR. Cells were cultured in DMEM (Gibco, NYS, USA) which was added with 4.5 g/L glucose, 10% fetal bovine serum (FBS) (Gibco, NYS, USA), and 1% penicillin–streptomycin (PS) (Sigma, St Louis, MO, USA) at 37 °C in a humidified incubator with 5% CO₂.

Establishment of stable GEM-R and GEM-R-hENT1 cell lines
Gemcitabine-resistant MDA-MB-231 (GEM-R) cells and GEM-R cells with exogenous expression of the hENT1
gene (GEM-R-hENT1) were established as described in our previous study [51].

GEM-R cells were obtained by culturing WT cells in DMEM containing GEM for 24 h, followed by culturing in fresh medium without GEM for about one-week recovery until stable proliferation was observed. For the GEM exposure, stepwise incremental doses from 1 to 20 μM were applied. The development was repeated for at least two cycles (Fig. 2A).

To obtain GEM-R-hENT1 cells, recombinant lentivirus plasmids LV-EF1α-IRES-puro and LV-EF1α-hENT1-IRES-puro were constructed by Shanghai Xitubio Biotechnology Co., Ltd. hENT1 amplification was confirmed by RT-PCR. For transfection, GEM-R cells were plated in 6-well plates (2 × 10^5 cells per well) and cultured in DMEM for 24 h. Culture medium containing 8 μg/mL polybrene (SiDanSai Biotechnology Co., Ltd, Shanghai, China) was mixed with lentiviral supernatant at a ratio of 1:1 and added to each well, and the medium was changed after 24 h incubation. Cells stably expressing hENT1 were screened with 2 μg/mL puromycin (Sangon Biotech, Shanghai, China).

**MiRNA transfection**

Cells were transfected with MicrON™ has-miR-143-3p mimic (RiboBio, Guangzhou, China) using Lipofectamine 2000 (Invitrogen, MA, USA) according to the manufacturer’s protocol. After cell seeding into plates, Lipofectamine 2000 reagent was diluted in Opti-MEM (medium A) and micrON™ has-miR-143-3p mimic was diluted in Opti-MEM medium (medium B) respectively (for different samples, the dilution varies). Then, diluted medium A and B were added at a ratio of 1:1 to incubate for 5 min at room temperature to get the RNA-lipid complex. Next, the RNA-lipid complex was added to each well to get cells transfected.

**Cell counting kit-8 (CCK-8) assays**

The IC_{50} of all cell lineages was measured. Approximately 6 × 10^3 cells per well were seeded in 96-well plates. Then, a gradient concentration of GEM from 0 to 2 mM was added to the culture medium, and cells were grown for 72 h. Cytotoxicity was evaluated using the CCK-8 assay (Beyotime Biotechnology, Shanghai, China) according to the manufacturer’s instructions. After 2 h of the addition of CCK8, the absorbance value was measured at 450 nm with an enzyme-labeled-meter (Thermo Fisher Scientific, multitokan MK3). IC_{50} was defined as the GEM concentration that killed 50% of cells. All experiments were performed in triplicate and repeated independently three times.

The viability of MDA-MB-231 and GEM-R cells was determined. Cells were seeded in 96-well plates at a density of 6,000 per well and cultured in DMEM with and without glucose. After 72 h incubation, CCK8 assay was performed as described above.

**Flow cytometry for apoptosis detection**

Apoptosis was measured by a flow cytometry detector (Beckman Cytoflex S) using the Annexin V-FITC Apoptosis Detection kit (Sigma, St Louis, MO, USA) following the manufacturer’s instructions.

Cells are seeded in 6-well plates at a density of 1 × 10^5/ml. After 72 h of dosing treatment, the upper medium

---

**Table 1** Primer sequences for Real-time PCR

| Primer sequences | Forward | Reverse |
|------------------|---------|---------|
| hENT1 | 5′-CTGGCTCTTCTCTGCTGCTTCA-3′ | 5′-CTCAACAGTCACGCGCTGAA-3′ |
| miR-143 | 5′-ACAACCTCAGGTTAGATGAAAGCCTGT-3′ | 5′-CCTCAACTGTTGTCGAGGTGGC-3′ |
| HK2 | 5′-AAGGCTTCAAGGCATCG-3′ | 5′-AAGGCTTCAAGGCATCG-3′ |

**Table 2** Antibodies for Western blot and immunohistochemistry

| Name | Antibody type | Host | Target species | Purification | Experiment | Company |
|------|---------------|------|----------------|--------------|------------|---------|
| hENT1 | Primary | Rabbit | hENT1 | polyclonal | WB/IHC | Abcam |
| HK2 | Primary | Rabbit | HK2 | monoclonal | WB/IHC | Abcam |
| β-Actin | Primary | Mouse | β-Actin | monoclonal | WB | Abcam |
| Goat anti-rabbit HRP | Secondary | Goat | Rabbit IgG | / | WB/IHC | Abcam |
| Goat anti-mouse HRP | Secondary | Goat | Mouse IgG | / | WB/IHC | Abcam |

*WB western blot, IHC immunohistochemistry*
(v1) of each well is collected separately in flow cytometry tubes (flow cytometry tubes are labeled according to the sample wells). Cells are then washed twice with 1 × PBS buffer, and the wash solution (v2) is also collected separately in new flow cytometry cell tubes. 100 μl of EDTA-free trypsin (Beyotime Biotechnology, Shanghai, China) was added to each well to completely cover the cells at the bottom of the wells. After about 1–2 min’ digestion, v1 medium was added to corresponding well to terminate digestion.

Next, cells were centrifuged at 500g, 4 °C in an ultracentrifuge to get cell suspension. Then cells were washed twice with 1 × PBS buffer. Cells were resuspended in 200 μl Binding Buffer (1 ×). 5 μl FITC was added into the cell suspension, well mixed and incubated for 10 min at room temperature. Cells were washed with 200 μl binding buffer (1 ×) and resuspended in 95 μl binding buffer (1 ×). Before detection, 5 μl of propidine iodide was added to cell suspension and apoptosis was detected by a cell flow cytometry detector (Beckman Cytoflex S).

**Real-time PCR**

The expression levels of hENT1, miR-143, and HK2 were determined by real-time PCR on a Viia™ 7 Real-Time PCR System (Applied Biosystems). RNA was extracted using the RNaseasy Mini Kit (Qiagen, Germany) and reverse-transcribed into cDNA using the PrimeScript RT Master Mix (TAKARA, Japan). The primer sequences are listed in Table 1. Amplification conditions included a denaturation step at 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s, 60 °C for 30 s, and 72 °C for 5 min. Relative mRNA expression was evaluated using the 2−ΔΔCt method (β-actin as endogenous reference).

**Western blotting**

Proteins were extracted from GEM-R and GEM-R-hENT1 cells using RIPA buffer (Sigma, St Louis, MO, USA), and protein concentration was determined using the BCA Protein Assay Kit (Beyotime Biotechnology, Shanghai, China). 7.5% PAGE Gel Fast Preparation Kit (Epizyme, Shanghai, China) was used to prepare gels. Protein samples were mixed with 5 × loading buffer from Epizyme at a volume ratio of 4:1, boiled at 100°C for 10 min, electrophoresed, and transferred to a polyvinylidene fluoride membrane (Sangon Biotech, Shanghai, China). The membrane was blocked in protein-free rapid blocking buffer (1 ×) for 10 min and incubated with a primary antibody against ENT1 (Abcam, UK; Table 2) and β-actin at dilutions of 1:1000 at 4°C overnight. The membrane was washed with TBST three times and incubated with HRP-labeled anti-rabbit/mouse secondary antibody (Abcam, UK; Table 2) for 1 h at room temperature. Bands were visualized using the ChemiDoc XRS system (BioRad) and quantified using ImageJ version 1.5. grayscale value ratio = The area of the target protein band/ The area of the endogenous reference protein band. For GEM-R cells treated with and without miR-143, primary antibodies against HK2 and β-actin (Abcam, UK; Table 2) at dilutions of 1:1000 were used.

**Multiple reaction monitoring (MRM) analysis and GEM uptake determination**

The concentration of GEM was quantified using a HPLC System (LC-30A, SHIMADZU, JAPAN) coupled with a triple quadrupole mass spectrometer (QTRAP6500, SciEX, USA) for MRM analysis (264.1/112.1). Capillary voltage was set at 4500 V. MRM Declustering Potential (DP), Entrance Potential (EP), Collision Energy (CE), Collision Cell Exit Potential (CXP) were optimized for each metabolite by FIA mode. The detection was operated in positive mode. A total of 2 μl sample was separated on an Accucore™ C18 column (2.1 × 100 mm) with solvent A (95% H2O/5% Acetonitrile [ACN]/0.1%Formic acid [FA]) and solvent B (95% ACN/H2O/0.1%FA). The flow rate was set at 0.3 mL/min and the column temperature was kept at 40 °C. Elution was completed by holding 90% A and 10% B for 0.3 min, then a linear gradient to 90% B and 10% A within 4 min and the system returned to the initial conditions within 30 s.

WT, GEM-R and GEM-R-hENT1 cells were cultured in cell culture dishes and incubated in a cell culture incubator. When cells were grown to the confluent of 70%~80%, 10 μM GEM was added to each cell dish and mixed thoroughly with the medium. For the GEM uptake determination, each cell sample (about 3 × 106 cells) was added with 1 ml 50% methanol water solution. After repeated freezing and thawing in liquid nitrogen, the cells were completely broken and were centrifuged at 13200 rpm for 20 min at 4 °C. The supernatants were lyophilized and redissolved in methanol/acetonitrile/ water solution (2:2:1). The mixture was vortexed until all the precipitates were dissolved and then centrifuged again. The supernatants were added to the loading bottle for detection.

The GEM standard curve was established with 19 standard solutions in the range between 10 and 1000 ng/mL (r²>0.99). The amount of GEM uptake of WT, GEM-R and GEM-R-hENT1 cells was determined by calculating the area under the elution peak and the area of the standard curve.

**Measurement of glucose consumption and in vitro ¹⁸F-FDG uptake**

WT, GEM-R, and miR-143-treated GEM-R cells were cultured in glucose-free DMEM in 24-well plates for 2 h at cell density of 1 × 105/ml. Then for each well, cells were added with five microliters of DMEM containing 4.5 g/L
glucose and were grown for another 1 h. A glucose assay kit (Sigma) was utilized to measure glucose concentration in the medium. To measure $^{18}$F-FDG uptake, cells were grown in 24-well plates for 24 h in a cell culture incubator, washed three times with PBS, and cultured in 200 μL of glucose-free medium containing 10 μM GEM. Experiments were carried out in triplicate. After 2 h incubation, 37 kBq/mL $^{18}$F-FDG was added to the medium, and cells were cultured for 1 h. The medium was aspirated into tubes for later testing. Ice-cold PBS was used for washing cells for three times and then was mixed with the medium as supernatants. Cells were digested with 0.25% trypsin and collected into another tube. Cold PBS was used for washing wells and was mixed with the cells. $^{18}$F-FDG radioactivity was measured in cells (B) and supernatants (F) by a gamma counter, and in vitro $^{18}$F-FDG uptake rate (%) was calculated according to the formula as previously described [52]: uptake rate (%) = \[ \frac{B}{B+F} \times 100\% \].

**Xenograft model and treatment experiments in vivo**

All animal experiments conformed to the guidelines of the Animal Care and Use Committee of Ruijin Hospital, School of Medicine of Shanghai Jiao Tong University, and to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Publication No. 8023, revised in 1978).

Five-week-old immunodeficient female BALB/c nude mice (Lingchang Animal Experiment Center) served as a subcutaneous xenograft model. MDA-MB-231, GEM-R, and GEM-R-hENT1 cells were injected subcutaneously into mice to establish three tumor models. Group allocation is shown in Tables 3, 4, 5. Gemcitabine dissolved in 0.9%NaCl solution (20 mg/kg) was injected intraperitoneally every 5 days for eight cycles. Mice treated with miR-143 were injected with 2 nmol of miRNA agomir into the tumor site every 3 days for eight cycles (Fig. 3A). The tumor volume growth curve was analyzed by measuring tumor length (L) and width (W) every 2 days and tumor volume using the formula (LW/2). Body weight was measured every 2 days to assess the adverse effects of chemotherapy.

The Cy3-labeled micrON™ miR-143 agomir was synthesized by RiboBio (Guangzhou, China) for histological fluorescence detection of miR-143.

**18F-FDG PET/CT analysis in vivo**

$^{18}$F-FDG PET/CT scan was performed on tumor-bearing mice using an Inveon small-animal PET/CT system (Siemens, Munich, Germany). Anesthesia was induced with 2% isoflurane and maintained via intraperitoneal injection of 1.25% avertin (100 μl/10 g). Mice were injected with 0.1 mL of $^{18}$F-FDG (130 μCi) in the tail vein and imaged with PET/CT (Siemens Inveon) under...
anesthesia (5-min CT scans followed by 10-min PET scans). PET images were reconstructed on an Inveon Acquisition Workplace using the 3D OSEM algorithm. The region of interest was selected on CT images and transferred to PET images. The standardized uptake value (SUV) of $^{18}$F-FDG was computed using the formula: \[ \text{SUV} = \frac{\text{decay-corrected activity (kBq)} \text{ per milliliter of tissue volume}}{\text{activity of injected } ^{18}\text{F-FDG (kBq)}/\text{body mass (g)}}. \]
Under 1% isoflurane induced anesthesia, mice were performed euthanasia by intraperitoneal injection of 1% pentobarbital sodium dissolved in saline water (200 μl/10 g) until no breath, heartbeat, neural reflex and muscle tension was observed.

Immunohistochemistry (IHC) and Fluorescence

Photography
Mice were sacrificed, and tumor samples were embedded in paraffin or snap-frozen to obtain cryosections. Paraffin-embedded sections were paraffinized, rehydrated in a graded ethanol series, and subjected to antigen retrieval. Samples were washed in phosphate-buffered saline (PBS) three times for 5 min under gentle shaking and blocked with 3% H2O2 for 25 min and 3% BSA for 30 min at room temperature. Sections were incubated with a primary antibody (anti-ENT1 and anti-HK2; Table 2) overnight at 4 °C and with an HRP-labelled secondary antibody for 1 h at room temperature. Next, peroxidase substrate DAB kit was utilized for visualization and slides were observed under a light microscope. For frozen slides from tumors injected Cy3-labeled micrON™ miR-143 agomir, Cy3 signaling was presented under a fluorescence microscope with cell nucleus dyed with DAPI.

Statistical analysis
All data were presented as mean ± SD. Pairwise comparisons were performed using Student’s t-test and GraphPad Prism version 6.0. P-values of less than 0.05 (denoted by *, **P < 0.01, ***P < 0.001 and ****P < 0.0001) were considered statistically significant.

Results

Correlation of prognosis or survivability with the expression of hENT1 in TNBC patients

High expression of hENT1 showed a significant association with favorable distal recurrence free survival in TNBC patients from GSE25066 and GSE69031 (Fig. 1A, p = 0.039). From the KM Plotter cohort study, TNBC patients with higher hENT1 expression exhibited better overall survival (Fig. 1B, p = 0.093), especially in basal-like subset TNBC patients (Fig. 1B, p = 0.037), suggesting a more precise identification of the role of hENT1 in TNBC prognosis.

Validation of GEM-R cells in vitro and in vivo

The viability and apoptosis of GEM-R cells were analyzed to evaluate resistance to GEM in vitro. The IC50 of GEM was higher in GEM-R cells than in WT cells (49.62 ± 0.34 μM vs. 26.10 ± 1.58 μM, p < 0.01) (Fig. 2B). The total rate of apoptosis was lower in GEM-R cells than in WT cells under the same treatment (16.25 ± 0.66% vs. 5.17 ± 0.73%, p < 0.0001) (Fig. 2C). In vivo, the inhibition of tumor growth by GEM was lower in GEM-R tumors than in WT tumors (p < 0.0001) (Fig. 3B). At the end of the treatment, the mean volume of GEM-R tumors was much bigger than WT tumors (Fig. 3B). There was no significant body weight loss across the groups during the treatment period (Fig. 3C). These results demonstrated that GEM-R cells are resistant to gemcitabine.

Mice of WT + GEM and GEM-R + GEM (Table 3) performed 18F-FDG PET/CT scan which presented the level of tumor glycolysis before and after treatment (Fig. 3D). The uptake of 18F-FDG after GEM treatment was significantly higher in mice bearing GEM-R tumors than in mice bearing WT tumors (mean SUVmax of 2.733 ± 0.81 and 1.425 ± 0.25, respectively; p < 0.01), demonstrating that the rate of proliferation was higher in GEM-R tumors than in WT tumors owing to the resistance to GEM and lead to higher level of glycolysis.

Upregulating hENT1 leads to higher apoptosis by inducing more GEM into cells

Lentivirus plasmids were transfected with gradient MOI (Multiplicity of Infection). The mRNA and protein expression levels of hENT1 increased with higher MOI (Fig. 4A&B). The uptake concentration of GEM in GEM-R cells increased with gradient MOI of hENT1 infection (Fig. 4C). 20.15 ± 13.4 ng/ml, 69.59 ± 17.2 ng/ml.

Table 3  Group allocation of WT and GEM-R tumor model mice to validate GEM resistance in vivo

| Treatment  | WT          | GEM-R        |
|------------|-------------|--------------|
| NaCl       | Y           | N            | Y            |
| GEM        | N           | Y            | N            |
| n          | 6           | 6            | 6            |

Note: Y Drug applied; N drug not applied

(See figure on next page.)

Fig. 3  Validation of GEM-R cell lines in vivo. Note: Data are represented as mean± SD. A TNBC tumor-bearing mice model and gemcitabine-resistant TNBC tumor model were established with 5-week-old BALB/c nude mice to validate chemoresistance of GEM-R cells we gained in vivo. B Tumor Volume growth curve was calculated to investigate the tumorigenesis and development of mice of WT and GEM-R tumor-bearing mice under GEM treatment (20 mg/kg/per every 5 days for 8 cycles). C Record of body weight of tumor bearing mice. D 18F-FDG microPET/CT scans were performed to analyze the maximum standardized uptake value (SUVmax) of 18F-FDG in chemo-therapy groups of GEM-R TNBC tumor bearing mice and TNBC tumor bearing mice before and after GEM treatment. White arrows point to tumors in mice
Fig. 3 (See legend on previous page.)
ml and 288.31 ± 44.1 ng/ml; MOI = 10 vs. 20, p < 0.001, MOI = 10 vs. 30, p < 0.0001). Higher uptake of GEM lead to higher rate of apoptosis (Fig. 4D, 4.12 ± 0.32%, 8.91 ± 1.3%, 10.50 ± 2.42%; MOI = 10 vs. 20, p < 0.0001; MOI = 10 vs. MOI = 30, P < 0.0001).

**Overexpression of hENT1 reverses GEM resistance in GEM-R cells and in vivo**

The mRNA (Fig. 5A) and protein expression (Fig. 5C) levels of hENT1 were lower in GEM-R cells than in WT cells. We overexpressed hENT1 in GEM-R cells to confirm the hypothesis that hENT1 overexpression reverses GEM resistance. The mRNA (Fig. 5B)
Fig. 5 Overexpression of hENT1 in GEM-R cells and its reversal of chemoresistance in vitro. Note: Data are represented as mean±SD. All experiments were performed in triplicate and repeated independently three times. A RT-PCR showed expression of hENT1 in mRNA level between WT and GEM-R cells. B RT-PCR showed overexpression of hENT1 in mRNA level in GEM-R-hENT1 cells compared with GEM-R cells. C Western blot showed expression of hENT1 in protein level of WT, GEM-R cells and GEM-R-hENT1 cells. Grayscale value ratio = The area of the target protein band/The area of the endogenous reference protein band. D CCK8 assay was used to evaluate IC_{50} of GEM-R cells and GEM-R-hENT1 cells to gradient concentration of GEM. E Percentage of cell apoptosis of GEM-R cells and GEM-R-hENT1 cells was evaluated by detection of flow cytometry with Annexin-V FITC/PI Apoptosis Detection Kit. F Uptake of GEM in WT, GEM-R and GEM-R-hENT1 cells by MRM analysis. Flow cytometric Annexin V−/P− represented normal cells; Annexin V−/P+ represented necrotic cells; Annexin V+/P− represented late apoptotic cells; Annexin V+/P+ represented early apoptotic cells.
and protein expression (Fig. 5C) levels of hENT1 were higher in GEM-R cells with exogenous expression of the hENT1 gene (GEM-R-hENT1 cells) than in GEM-R cells. The viability and apoptosis of GEM-R and GEM-R-hENT1 cells after GEM treatment were analyzed. The viability of GEM-R-hENT1 cells was lower than that of GEM-R cells under the same treatment (IC50 of 36.90 ± 0.80 µM and 49.62 ± 0.34 µM, respectively, p < 0.01) (Fig. 5D). In addition, the rate of apoptosis was higher in GEM-R-hENT1 cells than in GEM-R cells (10.50 ± 2.42% vs. 5.17 ± 0.73%, p < 0.01) (Fig. 5E). The uptake concentration of GEM in GEM-R-hENT1 cells (278.9 ± 8.61 ng/ml) was significantly higher than GEM-R cells (8.7 ± 1.13 ng/ml, p < 0.0001) and WT cells (71.2 ± 9.20 ng/ml, p < 0.01) (Fig. 5F). These findings indicated that hENT1 overexpression increased the influx of GEM, and thus reversed GEM resistance in GEM-R cells.

In vivo (Table 4), the tumor volume of mice bearing GEM-R-hENT1 tumors grew slower (Day 31, p < 0.05; Day 36, p < 0.001) than that of mice bearing GEM-R tumors after GEM treatment (Fig. 6A). No significant difference in body weight loss was observed across the groups during treatment (Fig. 6B). Immunohistochemistry showed that GEM-R-hENT1 tumors had higher hENT1 expression levels than GEM-R tumors (Fig. 6C). In addition, GEM decreased the uptake of 18F-FDG in the GEM-R-hENT1 group compared with the GEM-R group (mean SUVmax of 1.063 ± 0.21 vs. 2.733 ± 0.81, p < 0.01), suggesting that hENT1 overexpression reversed cancer drug resistance in vivo (Fig. 6D).

MiR-143 suppressed glycolysis in GEM-R cells
The result of GEM-R cells showing lower cell viability when cultured in the absence of glucose revealed that GEM-R cells were glucose-dependent and exhibited more active glycolysis (p < 0.01, Fig. 7A). We previously demonstrated that miR-143 mimic suppressed glycolysis in MDA-MB-231 cells by downregulating HK2 [47]. In the present study, GEM-R cells transfected with miR-143 mimic (p < 0.0001, Fig. 7B) also showed decreased mRNA (p < 0.0001) and protein expression of HK2 (Fig. 7C and D) as well as lower 18F-FDG uptake (p < 0.0001) and glucose metabolic rate (p < 0.001) than GEM-R cells without miR-143 treatment (Fig. 7E and F), indicating that miR-143 inhibited glycolysis in GEM-R cells by downregulating HK2.

MiR-143 enhanced the effect of reversing GEM resistance in GEM-R-hENT1 cells and in vivo
In vitro, the viability of miR-143-treated GEM-R-hENT1 cells was lower than that of miR-143-treated GEM-R and control GEM-R cells (IC50 of 14.71 ± 0.57 µM, 19.30 ± 0.59 µM, and 49.62 ± 0.34 µM, respectively; p < 0.0001, p < 0.0001 compared with control GEM-R cells) after GEM treatment (Fig. 8A). Similarly, the rate of apoptosis was higher in the first group than in the latter two groups (22.54 ± 1.03%, 11.79 ± 1.66% and 5.17 ± 0.73%, respectively; p < 0.0001, p < 0.0001; Fig. 8B).

In vivo (Table 5), tumor growth inhibition was higher in miR-143 + GEM-treated mice bearing GEM-R-hENT1 tumors than in miR-143 + GEM-treated mice bearing GEM-R tumors (p < 0.01) and control GEM-R tumors (p < 0.0001) after GEM treatment (Fig. 9A). In addition, there was no statistically significant difference in body weight across the groups (Fig. 9B). Moreover, 18F-FDG uptake was significantly lower in the group of GEM-R-hENT1 + GEM + miR-143 (p < 0.0001, Fig. 9C) with lower HK2 expression on immunohistochemical staining compared with the other two groups (Fig. 10A). Fluorescence imaging identified Cy3-labeled miR-143 agomir in the tumor tissues of the miR-143-treated groups (Fig. 10B). These results indicated that miR-143 inhibited glycolysis by regulating HK2 expression and reduced cancer drug resistance in a mouse xenograft tumor model, enhancing the effect of hENT1-induced reversal of GEM resistance.

Discussion
Gemcitabine resistance is a critical problem in the treatment of TNBC. In this study, we designed a combination therapy involving hENT1 overexpression and miR-143 administration, and investigated its efficacy in reversing GEM resistance in vitro and in an animal model of TNBC.

The nucleoside transporter hENT1 mediates GEM uptake in vitro and in vivo [25, 53, 54] and GEM resistance [27, 55, 56]. In this respect, Santini D et al. have shown that hENT1 expression is a prognostic marker in adjuvant therapy with GEM in patients with radically resected gastric cancer [57]. Marcé et al. [58] observed that the expression of hENT1 was closely correlated with GEM uptake and toxicity in mantle cell lymphoma. Our data suggested high expression of hENT1 generally predicted favorable prognosis in TNBC. It is

Table 4 Group allocation of treatment experiments in an animal model. Group allocation of GEM-R and GEM-R-hENT1 tumor model mice to validate hENT1 therapy in vivo

| Treatment | GEM-R | GEM-R-hENT1 |
|-----------|-------|-------------|
| GEM       | N     | Y           |
| n         | 6     | 6           |

Note: Y: Drug applied; N: Drug not applied
Fig. 6 Verification of therapeutic effect of hENT1 overexpression in vivo. Note: Data are represented as mean ± SD. A Tumor Volume growth curve was calculated to investigate the tumorigenesis and development of mice of each group. B Record of body weight of tumor bearing mice. C Photographs (365 x) of immunohistochemistry staining on hENT1 of tumor sample. D $^{18}$F-FDG microPET/CT scans were performed to analyze the maximum standardized uptake value (SUVmax) of $^{18}$F-FDG in GEM-R TNBC tumor bearing mice and GEM-R-hENT1 tumor bearing mice before and after GEM treatment. White arrows point to tumors in mice.
worth noting that hENT1 was significantly associated with increased overall survival in basal-like 1 subset in TNBC patients. Given that TNBC is particularly heterogeneous in breast cancer, further study for hENT1 expression in stratification of TNBC patients were required.

We found that upregulating the expression of hENT1 reversed GEM resistance in TNBC by mediating GEM influx into tumor cells [25] and inhibited tumor growth. However, the effect on reversing GEM resistance of increase in hENT1 levels and GEM influx in GEM-R-hENT1 cells was limited and slow. There wasn’t obvious
Fig. 8 Efficacy of hENT1 adjuvant with miR-143 on gem-resistance in vitro. Note: Data are represented as mean ± SD. All experiments were performed in triplicate and repeated independently three times. A CCK8 assay was used to evaluate IC\textsubscript{50} of GEM-R cells, GEM-R cells transfected with miR-143 and GEM-R-hENT1 cells induced with miR-143 when treated with gradient concentration of GEM. B Percentage of cell apoptosis of GEM-R cells, GEM-R cells transfected with miR-143 and GEM-R-hENT1 cells induced with miR-143 was evaluated by detection of flow cytometry with Annexin-V FITC/PI Apoptosis Detection Kit. Flow cytometric: Annexin V-/P- represented normal cells; Annexin V-/P+ represented necrotic cells; Annexin V+/P+ represented late apoptotic cells; Annexin V+/P- represented early apoptotic cells.
inhibition of tumor growth until Day 31 during the late stages in the treatment and there were large individual differences in tumor growth inhibition rate, possibly because of high redundancy in transport which meant only part of the hENT1 protein we upregulated played a role [45].

Furthermore, glycolysis was found to be higher in GEM-R cells than in WT cells in our study, suggesting that GEM resistance was accompanied by increased glycolysis [59]. Under aerobic conditions, tumor cells have higher glycolytic activity and reduced oxidative phosphorylation (Warburg effect) [60]. There were three reasons: to prepare glycolytic intermediates into the pentose phosphate pathway (PPP) for the rapid proliferation of tumor cells [61], to faster content a sudden increase of energy demand [62, 63], to protect tumor cells against oxidative stress [61]. Icard et al. reported [64] that the Warburg effect determines the aggressiveness and drug resistance of cancer cells partly by accelerating epigenetic and genetic changes. Enhanced glycolysis promotes drug resistance in pancreatic cancer [65], glioblastoma [66], and breast cancer [67]. Dai et al. proved that pancreatic cancer cell survival and tolerance to GEM were reduced by 2-deoxy-D-glucose-induced inhibition of glycolysis [65]. Moreover, TNBC exhibits abnormally increased glucose uptake and depends more on glycolysis than other breast cancer subtypes [68, 69]. Its possible mechanisms included a) the downregulation of transporters such as hENT1 in GEM-R cells decreased adenosine entry into cells, and adenosine accumulation in the extracellular environment stimulated increase of glycolysis in tumor cells to generate energy through the AMPK pathway [35, 36], b) our previous study [51] indicated that c-Myc and HIF-1α, two key regulators of glucose transport and metabolism, were more highly expressed in GEM-resistant pancreatic cancer cells than GEM-sensitive cells, confirming the crosstalk between glycolysis and chemoresistance. Therefore, the inhibition of glycolysis can potentially enhance the therapeutic effect of hENT1 treatment in GEM-R cells.

As a glycolysis inhibitor, miR-143 inhibited glycolysis in breast cancer cells [42] by downregulating the expression of HK2, which is a pivotal regulator of aerobic glycolysis and tumor growth [70, 71], and the systemic delivery of miR-143 agomir inhibited tumor growth [47]. Li et al. showed that miR-143 as significantly decreased in TNBC, and miR-143 overexpression could reduce the proliferation of TNBC cells by regulating the LIMK1/CFL1 pathway [72]. In the present study, we demonstrated that miR-143 reduced drug resistance in GEM-R cells by suppressing glycolysis and enhanced the effect of GEM reversal of hENT1 overexpression. Further combination therapy involving hENT1 overexpression and miR-143 administration achieved a higher tumor growth inhibition rate than hENT1 or miR-143 treatment alone, which can potentially be used to reverse drug resistance in TNBC. Without GEM resistance, GEM functions as a cytidine analog and strongly induces apoptosis [73, 74] in breast cancer in vitro and in vivo [75].

There are some limitations in our study. First, exogenously upregulating the expression of hENT1 through transfection of recombinant lentivirus may have potential biosafety risks. Second, miR-143 was administered by intratumor injection; therefore, additional studies are necessary to assess whether miR-143 mimic can produce a considerable inhibitory effect on GEM-resistant TNBC tumors through systemic administration. Third, the detail mechanism by which miR-143 reverses GEM resistance needs further exploration. Fourth, the regulation of drug efflux by ATP-binding cassette transporters, which [76] have also been shown to reverse drug resistance in breast cancer cells, was not investigated in the present study.

Conclusions
Increased hENT1-mediated GEM influx into GEM-R cells reversed GEM resistance and miR-143-mediated inhibition of glycolysis could significantly enhance this effect. Thus, hENT1 combined with miR-143 is a promising strategy for treating GEM-resistant TNBC.

---

**Table 5** Group allocation of treatment experiments in an animal model. Group allocation of GEM-R and GEM-R-hENT1 tumor model mice to validate dual-gene therapy in vivo

| Treatment     | GEM-R | GEM-R-hENT1 |
|---------------|-------|-------------|
| GEM           | Y     | Y           |
| MiR-143       | N     | N           |
| n             | 6     | 6           |

Y: Drug applied; N: Drug not applied

---

**Fig. 9** Efficacy of hENT1 adjuvant with miR-143 on gem-resistance in vivo. Note: Data are represented as mean ± SD. A Tumor Volume growth curve was calculated to investigate the tumorigenesis and development of mice of each group. B Record of body weight of tumor bearing mice. C 18F-FDG microPET/CT scans were performed to analyze the maximum standardized uptake value (SUVmax) of 18F-FDG in GEM-R TNBC tumor bearing mice and GEM-R-hENT1 tumor bearing mice before and after GEM treatment or GEM-miR-143 dual treatment.
Fig. 9 (See legend on previous page.)
**Fig. 10** Tumor sample detection of mice model of hENT1 adjuvant with miR-143 on gem-resistance.

**A.** Photographs (200×) of immunohistochemistry staining on HK2 of tumor samples.

|        | GEM-R     | GEM-R     | GEM-R-hENT1 |
|--------|-----------|-----------|-------------|
| GEM    | +         | +         | +           |
| miR-143| -         | +         | +           |

**B.** Fluorescence photography (200×) was applied to detect Cy3 signals to support the administration of miR-143 agomir in the tumors.

|        | GEM-R     | GEM-R     | GEM-R-hENT1 |
|--------|-----------|-----------|-------------|
| GEM    | +         | +         | +           |
| miR-143| -         | +         | +           |
Abbreviations
TNBC: Triple-negative breast cancer; WT: MDA-MB-231; GEM-R: Gemcitabine-resistant MDA-MB-231; GEM-R-hENT1: GEM-R cells with exogenous expression of the hENT1 gene.

Acknowledgements
This work was supported by the National Natural Science Foundation of China (No. 81871378; 81501499). We thank Mass Spectrometry Platform, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China for MRM analysis.

Author contributions
BL performed study concept and design; MZ performed review and revise of the manuscript; YX provided the acquisition and analysis of data and draft of the article; TL, YY, XYZ, MY carried out the experiments; RG provided technical support. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Nos. 81871378; 81501499).

Availability of data and materials
The datasets used during the study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All animal experiments conformed to the guidelines of the Animal Care and Use Committee of Ruijin Hospital, School of Medicine of Shanghai Jiao Tong University, and to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Publication No. 8023, revised in 1978). Tumor samples were immediately snap-frozen and stored at -80℃ and the specimens collection was approved by the Medical Ethical Committee of the University, and to the National Institutes of Health Guide for the Care and Use Committee of Ruijin Hospital, School of Medicine of Shanghai Jiao Tong University School of Medicine, Shanghai, China for MRM analysis.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Author details
1Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China. 2Collaboration Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Center, Shanghai 200025, China. 3Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Received: 14 October 2021   Accepted: 11 August 2022
Published online: 01 September 2022

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Warner E. Clinical practice. Breast-cancer screening. N Engl J Med. 2011;365(1):1025–32.
3. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409–18.
4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
5. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol. 2005;34(2):405–12.
6. Boffetta P, Parkin DM. Cancer in developing countries. CA. 1994;44(2):81–90.
7. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12(Suppl 1):570-80.
8. Kim C, Gao R, Siei E, Brandt R, Hartman J, Hetchek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879-93.e13.
9. Foulkes WD, Smith IE, Reiss-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.
10. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.
11. Brown M, Toddkov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004. Cancer. 2008;112(4):737–47.
12. Garrido-Castro AC, Lin NU, Poljak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(12):176–98.
13. Gadi VK, Davidson NE. Practical approach to triple-negative breast cancer. J Oncol Pract. 2017;13(5):293–300.
14. Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAHM perspective. Cancer Chemother Pharmacol. 2016;78(1):1–12.
15. de Sousa CL, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16.
16. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology. 2003;64(3):191–206.
17. Yardley DA, Coleman R, Conte P, Cortes J,布鲁夫斯基 A, Shtivelband M, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the trACtY trial. Ann Oncol. 2018;29(8):1763–70.
18. Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CIBSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(4):436–46.
19. Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol. 2011;18(4):180–90.
20. Alghafeh A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, et al. Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance. Clin Cancer Res. 2017;23(13):3365–70.
21. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Investig. 2011;121(10):3810–8.
22. Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J. 1990;272(2):281–95.
23. Kohan HG, Boroujerdi M. Time and concentration dependency of P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in Capan-2 pancreatic cancer cells. Xenobiotica. 2015;45(7):642–52.
24. Giller JP, Gottsman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010;596:47–76.
25. Mackey JR, Mani RS, Selner M, Mowles D, Youn YD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Can Res. 1998;58(19):4349–57.
26. Mackey JR, Baldwin SA, Young JD, Cass CE. Nucleoside transport and its significance for anticancer drug resistance. Drug Resist Updates. 1998;1(5):310–24.
27. Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Visanska M, et al. Immunohistochemical variation of human equilibrative nucleoside transporters in primary breast tumors.
transporter 1 protein in primary breast cancers. Clin Cancer Res. 2002;8(1):110–6.

28. Cass CE, King KM, Monteath JT, Janowska-Wieczorek A. A comparison of the abilities of nitrobenzylthionine, dilazep, and dipipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Can Res. 1992;52(21):5879–86.

29. Cass CE, Kolassa N, Uehara Y, Dahlig-Harley E, Harley ER, Paterson AR. Absence of binding sites for the transport inhibitor nitrobenzylthionine on nucleoside transport-deficient mouse lymphoma cells. Biochem. Biophys. Acta. 1981;649(3):769–77.

30. Hesler RA, Huang JI, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, et al. TGF-β-induced stromal CRY161 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis. 2016;37(11):1041–51.

31. Wattanawongdon W, Hahnvajanawong C, Namwat N, Kanchanawat S, Boonmars T, Jearanaikoon F, et al. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Int J Oncol. 2015;47(1):398–410.

32. Espinoza JA, García P, Bizama C, Leal JL, Riquelme I, Weber H, et al. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naive pt2 gallbladder adenocarcinoma patients. Histopathology. 2016;69(5):722–8.

33. Greenhall W, Ghanef P, Neopolemos JP, Palmer DH, Cox TF, Lamb RF, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014;106(10):djt347.

34. Sève P, Mackey JR, Isaac S, Téldan O, Souquet PJ, Péról M, et al. nN-III expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2005;49(3):363–70.

35. Zhang D, Xiong W, Albenic BS, Parkinson FE. Expression of human equilibrative nucleoside transporter 1 in mouse neurons regulates adenine levels in physiological and hypoxic-ischemic conditions. J Neurochem. 2011;118(1):4–11.

36. Logie L, Lees Z, Allwood JW, McDougall G, Beall C, Rena G. Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1). Diabetes Obes Metab. 2018;20(12):2748–58.

37. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.

38. van Rooij E. The art of microRNA research. Circ Res. 2011;108(2):219–34.

39. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.

40. Zhao S, Liu H, Liu Y, Wu J, Wang C, Hou X, et al. miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. Cancer Lett. 2018;396:189–99.

41. Chen J, Yu Y, Li H, Hu Q, Chen X, He Y, et al. Long non-coding RNA PVT1 targets oncogenes in the molecular pathogenesis of lung adenocarcinoma. Int J Mol Sci. 2019;20:18.

42. Santini D, Vincenzi B, Fratto ME, Perone G, Lai R, Catalano V, et al. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol. 2010;223(2):384–8.

43. Miao Y, Zhang LF, Guo R, Liang S, Zhang M, Shi S, et al. (18)F-FDG PET/CT for monitoring the response of breast cancer to miR-143-based therapy. Mol Ther Nucleic Acids. 2016;5(8):e357.

44. Nedeljkovic M, Damjanovic A. Mechanisms of chemotherapy resistance and enhanced invasiveness in triple-negative breast cancer patients receiving a taxane-based chemotherapy. J Pers Med. 2021;11:3.

45. Xi Y, Yuan R, Li T, Zhang M, Liu MF, Li B. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Lett. 2020;479:112–22.

46. Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W, et al. MicroRNAs involved in cancer progression, prognosis, therapeutic resistance and applications in human triple-negative breast cancer. Cells. 2019;8:12.

47. Miao Y, Zhang LF, Guo R, Liang S, Zhang M, Shi S, et al. (18)F-FDG PET/CT for monitoring the response of breast cancer to miR-143-based therapy targeting tumor glycolysis. Mol Ther Nucleic Acids. 2016;5(8):e357.

48. Gyöffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–9.

49. Shen N, Korm S, Karantanos T, Li D, Zhang X, Ritoé E, et al. DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. Commun Biol. 2021;4(1):1289.

50. Cheng SW, Chen PC, Ger TR, Chiu HW, Lin YF. GBP5 serves as a potential marker to predict a favorable response in triple-negative breast cancer patients receiving a taxane-based chemotherapy. J Pers Med. 2021;11:3.

51. Xi Y, Yuan R, Li T, Zhang M, Liu MF, Li B. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Lett. 2020;479:112–22.

52. Li T, Tan X, Yang R, Miao Y, Zhang M, Xi Y, et al. Discovery of novel glyceraldehyde-3-phosphate dehydrogenase inhibitor via docking-based virtual screening. Bioorg Chem. 2020;96:103620.
tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313–26.
72. Li D, Hu J, Song H, Xu H, Wu C, Zhao B, et al. miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res. 2017;9(12):2276–85.
73. Ando T, Ichikawa J, Fujimaki T, Taniguchi N, Takayama Y, Haro H. Gemcitabine and rapamycin exhibit additive effect against osteosarcoma by targeting autophagy and apoptosis. Cancers. 2020;12:11.
74. Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res. 2005;23(4):964–9.
75. Mini E, Nobili S, Caciagli R, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7-12.
76. Wang Y, Zhao L, Xiao Q, Jiang L, He M, Bai X, et al. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol. 2016;141(3):592–601.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.